UBS initiates Amrize stock coverage with neutral rating on growth outlook

UBS initiated coverage on Amrize Ltd (AMRZ) with a Neutral rating and a $53.00 price target, citing attractive medium-term growth potential from strong U.S. construction fundamentals, tempered by short-term interest rate headwinds. The investment bank projects $8.05 billion in free cash flow between 2025-2028, slightly exceeding company guidance, which could support future M&A. However, UBS notes the shares are trading near fair value, with current prices already reflecting significant growth expectations, including a 14.5% perpetual post-tax return on invested capital.

Analysis

UBS has initiated coverage on Amrize Ltd (AMRZ) with a Neutral rating and a $53.00 price target, reflecting a balanced view of the company's prospects. The firm highlights Amrize's attractive medium-term growth potential, which is underpinned by strong fundamentals in the U.S. construction market. UBS projects free cash flow generation of $8.05 billion between 2025 and 2028, slightly surpassing the company's own guidance and providing potential capital for future M&A. However, this positive outlook is tempered by short-term headwinds from the current interest rate environment and a valuation that UBS considers to be fair. The shares are currently trading at 8.9 times EV/EBITDA with a 6% free cash flow yield based on 2026 estimates. Critically, the current stock price already implies a perpetual post-tax return on invested capital of approximately 14.5%, a significant premium to the roughly 10% expected in 2025, suggesting that substantial future growth is already priced in by the market.

Key Decisions for Investors

• Given the stock is trading near fair value with high expectations already priced in, investors may consider holding existing positions rather than initiating new ones, as the risk/reward profile appears balanced.
• Potential investors should exercise caution and monitor for a more attractive entry point, which could arise if short-term interest rate headwinds negatively impact the share price.
• Investors should closely track Amrize's ability to elevate its return on invested capital (ROIC) towards the 14.5% level implied by its valuation, as failure to achieve this could lead to a de-rating of the stock.